DE69636777D1 - Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen - Google Patents

Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen

Info

Publication number
DE69636777D1
DE69636777D1 DE69636777T DE69636777T DE69636777D1 DE 69636777 D1 DE69636777 D1 DE 69636777D1 DE 69636777 T DE69636777 T DE 69636777T DE 69636777 T DE69636777 T DE 69636777T DE 69636777 D1 DE69636777 D1 DE 69636777D1
Authority
DE
Germany
Prior art keywords
treatment
solid tumors
vectors
diagnosis
parasites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636777T
Other languages
English (en)
Inventor
M Pawelek
David Bermudes
B Low
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of DE69636777D1 publication Critical patent/DE69636777D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69636777T 1995-06-07 1996-06-05 Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen Expired - Lifetime DE69636777D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48642295A 1995-06-07 1995-06-07
US08/658,034 US6190657B1 (en) 1995-06-07 1996-06-04 Vectors for the diagnosis and treatment of solid tumors including melanoma
PCT/US1996/010250 WO1996040238A1 (en) 1995-06-07 1996-06-05 Vectors for the diagnosis and treatment of solid tumors including melanoma

Publications (1)

Publication Number Publication Date
DE69636777D1 true DE69636777D1 (de) 2007-02-01

Family

ID=27048679

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636777T Expired - Lifetime DE69636777D1 (de) 1995-06-07 1996-06-05 Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen

Country Status (15)

Country Link
US (3) US6190657B1 (de)
EP (1) EP0833660B1 (de)
JP (1) JP3482213B2 (de)
KR (1) KR100435932B1 (de)
CN (1) CN1138563C (de)
AT (1) ATE348634T1 (de)
AU (1) AU719446B2 (de)
BR (1) BR9609016A (de)
CA (1) CA2224075C (de)
DE (1) DE69636777D1 (de)
HK (1) HK1017253A1 (de)
IL (1) IL122407A (de)
MX (1) MX9709439A (de)
NZ (1) NZ312341A (de)
WO (1) WO1996040238A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
AU752753B2 (en) * 1997-04-09 2002-09-26 Lung-Ji Chang Animal model for evaluation of vaccines
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
AU7993600A (en) * 1999-10-04 2001-05-10 Sloan-Kettering Institute For Cancer Research Non-invasive tumor imaging by tumor-targeted bacteria
MXPA02003384A (es) * 1999-10-04 2002-08-20 Vion Pharmaceuticals Inc Composiciones y metodos para atacar tumores y entrega de moleculas determinantes.
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU7856100A (en) * 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
DE60141773D1 (de) * 2001-04-20 2010-05-20 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
EP2518142B1 (de) * 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7015027B1 (en) * 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
AU2004204751A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
CA2517158A1 (en) * 2003-03-03 2004-09-16 University Of Victoria Innovation And Development Corporation Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
DE602004027902D1 (de) 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
ATE420160T1 (de) 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP1643969A2 (de) * 2003-07-11 2006-04-12 Pro-Pharmaceuticals, Inc. Zusammensetzungen und verfahren für die hydrophobe arzneimittelabgabe
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7390646B2 (en) 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
PL1694845T3 (pl) * 2003-11-28 2019-01-31 National Research Council Of Canada Przeciwciała przeciwko rakowi i ich zastosowania
EP1718146A2 (de) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von akne und candida
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
PL1765391T3 (pl) * 2004-06-07 2013-08-30 Qu Biologics Inc Kompozycje bakteryjne do leczenia nowotworów
US8822194B2 (en) 2004-06-29 2014-09-02 Anticancer, Inc. Cancer selective auxotrophs
EP1773128A2 (de) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verbesserung der chemotherapie mit mikrobiellen zytotoxinen
DE602005025946D1 (de) 2004-11-24 2011-02-24 Anaeropharma Science Inc Neuartiger Shuttle-Vektor
US7785872B2 (en) * 2004-12-08 2010-08-31 Simpson Biotech Co., Ltd. Nucleic acids for enhancing gene expression and use thereof
US8734779B2 (en) * 2005-04-08 2014-05-27 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
KR101365538B1 (ko) 2005-06-14 2014-02-21 프로톡스 테라페유틱 인코포레이티드 변형된 포어 형성 단백질을 이용하여 양성 전립선 비대를치료하거나 예방하는 방법
WO2007079351A2 (en) * 2005-12-15 2007-07-12 Aeras Global Tb Vaccine Foundation Novel prime-boost combinations of attenuated mycobacterium
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
WO2008141226A2 (en) * 2007-05-10 2008-11-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
EP2171071B1 (de) * 2007-06-15 2015-08-05 Genelux Corporation Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
WO2009011924A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
CN101112398A (zh) * 2007-08-28 2008-01-30 罗舒仓 伤寒、副伤寒沙门菌快速抗肿瘤方面的应用
US9040059B2 (en) 2007-10-05 2015-05-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting a protective immune response against C. perfringens
US20090136917A1 (en) * 2007-10-25 2009-05-28 Szalay Aladar A Systems and methods for viral therapy
WO2009126310A2 (en) 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
WO2010137900A2 (ko) 2009-05-27 2010-12-02 전남대학교 산학협력단 선택적 경색 조직 타겟팅 박테리아 및 그의 용도
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011150421A2 (en) * 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US9675814B2 (en) 2011-05-09 2017-06-13 Innovolink, Llc Apparatus and method for obtaining a substantially constant current across a treatment region
US9901387B2 (en) 2011-05-09 2018-02-27 Innovolink, Llc Apparatus and method for heating adipose cells
US9901742B2 (en) 2011-05-09 2018-02-27 Innovolink, Llc Apparatus and method for heating a treatment region with an alternating electric field
US9956028B2 (en) * 2011-05-09 2018-05-01 Innovolink, Llc Apparatus and method for heating biological targets
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EA030573B1 (ru) 2013-01-02 2018-08-31 Дикой Байосистемз, Инк. Композиции и способы для лечения рака с применением бактерий
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
WO2015076663A1 (en) * 2013-11-22 2015-05-28 Universiti Putra Malaysia (Upm) Salmonella enterica serovar agona for anti-tumor therapy
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10076556B2 (en) 2015-01-29 2018-09-18 Oxyrase, Inc. Methods for inhibiting tumor growth
CN105983103A (zh) * 2015-03-17 2016-10-05 广州华津医药科技有限公司 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2018531606A (ja) * 2015-10-30 2018-11-01 ザ ジャクソン ラボラトリーＴｈｅ Ｊａｃｋｓｏｎ Ｌａｂｏｒａｔｏｒｙ 腫瘍分析に関する組成物及び方法
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7249279B2 (ja) 2016-12-07 2023-03-30 サルスペラ，リミティド ライアビリティ カンパニー がんの相乗的治療方法
US20180275027A1 (en) * 2017-03-22 2018-09-27 Slmp, Llc Cell yield for synthetic tissue controls and synthetic tissue microarray controls
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN112673092B (zh) 2018-07-11 2024-03-29 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3699263A1 (de) * 2019-02-22 2020-08-26 GlaxoSmithKline Biologicals S.A. Gärungsprozess
CA3131017A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4196139A2 (de) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Impfstoffe auf der basis von immunstimulierenden bakterien, therapeutika und rna-freisetzungsplattformen
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
ATE190660T1 (de) 1990-12-18 2000-04-15 Gen Hospital Corp Verbesserte impfstoffe
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
IL101409A0 (en) * 1992-03-29 1992-11-15 Era Masis Ltd Method for the early diagnosis of cancer
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector

Also Published As

Publication number Publication date
IL122407A0 (en) 1998-06-15
BR9609016A (pt) 1999-07-06
US6685935B1 (en) 2004-02-03
CA2224075C (en) 2011-10-04
CA2224075A1 (en) 1996-12-19
CN1138563C (zh) 2004-02-18
MX9709439A (es) 1998-02-28
JP3482213B2 (ja) 2003-12-22
EP0833660A1 (de) 1998-04-08
EP0833660B1 (de) 2006-12-20
ATE348634T1 (de) 2007-01-15
JP2000514400A (ja) 2000-10-31
KR19990022686A (ko) 1999-03-25
NZ312341A (en) 1999-05-28
AU6385196A (en) 1996-12-30
KR100435932B1 (ko) 2004-08-25
US20050036987A1 (en) 2005-02-17
CN1192694A (zh) 1998-09-09
AU719446B2 (en) 2000-05-11
WO1996040238A1 (en) 1996-12-19
US6190657B1 (en) 2001-02-20
IL122407A (en) 2007-09-20
EP0833660A4 (de) 2003-04-09
HK1017253A1 (en) 1999-11-19

Similar Documents

Publication Publication Date Title
DE69636777D1 (de) Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
DE69014030T2 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
DE59101948D1 (de) Alkalische bacillus-lipasen, hierfür codierende dna-sequenzen sowie bacilli, die diese lipasen produzieren.
ATE258185T1 (de) Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie
TR199900469T2 (xx) Ast�m �nleyici, antialerjik ve ba����kl�k bast�r�c�/ba����kl�k ayarlay�c� etkilere sahip N-s�bstit�e indol-3-glioksilamidler.
DE69126039T2 (de) Wirkstoff zur haarmodifikation und haarpflegeprodukt, die beide einen antikeratin-antikörper enthalten, und herstellung des antikeratin-antikörpers
DE69003650D1 (de) Aloewasser, herstellungsverfahren und mittel, die dieses enthalten.
ES2158356T3 (es) Nueva composicion oxidante y nuevo procedimiento para la deformacion permanente o la decoloracion de los cabellos.
PT876398E (pt) Inducao de respostas imunitarias contra determinantes desejados
AU538896B2 (en) Preparation of ribosomal rnas and immunostimulating preparations containing them
DE69003937D1 (de) Mittel für die diagnose und die behandlung der melanomen, halogenierte, aromatische derivate, verwendbar als solche mittel und ihre herstellung.
DE50011920D1 (de) Direkt verpressbarer rohstoff für komprimate
DE69840649D1 (de) Hydrophile zusammensetzung, die eine von vibrio proteolyticus hergestellte protease enthält
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
MX9700624A (es) Azolidinonas de imidazopiridina.
EP0777683A4 (de) Gegen protozoen wirksamezyklische tetrapeptide
DE69731388D1 (de) Nukleinsäure-fragmente, die spezifische für die mitglieder des m. tuberculosis komplexes sind, deren anwendung zur detektion und differentiale diagnose der mitglieder des m. tuberculosis komplexes
MX9700113A (es) Amido-quinoxalindionas novedosas, su preparacion y uso.
DE69625104D1 (de) Verwendung von chemischem Mittel für die Behandlung von Textilien
DiGennaro The Interest Checklist: Gender bias.
DE29505295U1 (de) Arbeits- bzw. Abdeckplatte für die Gehäuse von elektrischen Haushaltsgeräten
ATE138196T1 (de) Testverfahren für und behandlung von autoimmunkrankheiten
RU97111553A (ru) Штамм бактерий mycobacterium smegmatis вкпм ас-1552, используемый для окисления стеринов растительного и животного происхождения до андрост-4-ен-3,17-диона
Lee Dispute continues at South African university.

Legal Events

Date Code Title Description
8332 No legal effect for de